Ascend, Stanford to study SARS-CoV-2 exposure in patients on dialysis
Starting in July, researchers from Stanford University School of Medicine will collaborate with dialysis testing laboratory Ascend to examine the prevalence of SARS-CoV-2 antibodies in patients on dialysis, according to a press release.
“The high-risk dialysis patient population needs to interact with the health care system to receive life-sustaining therapy,” Paul F. Beyer, CEO of Ascend, told Healio Nephrology. “During a worldwide pandemic, this makes them especially vulnerable. Understanding their exposure to SARS-CoV-2 will be extremely valuable.”
Of the millions of samples Ascend processes each month, Beyer said the researchers will select a subsample of approximately 30,000 to 40,000 patients who are representative of the dialysis population in the United States, with consideration of age, gender, race/ethnicity and region.
Utilizing the SARS-CoV-2 Total Antibody assay (Siemens Healthineers), researchers will follow antibody responses for 12 months with estimations made as to the seroprevalence of SARS-CoV-2 antibodies. Beyer added that differences in seroconversion by age, sex, race/ethnicity and geographic regions will be explored.
“By following seroprevalence status over time, the study will estimate the potential need for health care capacity planning and vaccine requirements as the COVID-19 pandemic continues,” Beyer said.